Longer Breastfeeding in Infancy, Better School Grades for Kids?

Could breastfeeding lay the groundwork for good grades in high school?

That's what the findings of a new British study suggest, although the differences were small between those who were breastfed and those who weren't when it came to standardized test scores and grades.

"Breastfeeding promotes the development of the brain, which may...

AHA News: Celebrating Pride Month With Mental Health in Mind

As rainbow flags flutter in the June breeze for Pride Month, many LGBTQ+ people will feel tension in the air.

"It's been a really rough go for LGBTQ Americans" of late, said psychiatrist Dr. Natalia Ramos, an assistant clinical professor at the David Geffen School of Medicine at the University of California, Los Angeles.

In the wake ...

Can Some Cancer Patients Safely Skip Radiation Therapy? New Studies Say Yes

Radiation therapy might not be necessary in treating some forms of rectal cancer and lymphoma, sparing patients from the toxic treatment, a pair of new clinical trials shows.

One trial found that rectal cancer patients whose tumors shrink in response to chemotherapy can safely skip the radiation therapy that’s normally provided prior to ...

Money Troubles Can Delay Cancer Diagnoses, Putting Survival in Jeopardy

Money woes have long been linked to worse health care. Now, a new study finds financially strapped patients often put off cancer screenings -- only to learn they have the disease when it's advanced and tougher to treat.

Researchers studied the financial background of nearly 102,000 patients diagnosed with cancer between 2014 and 2015....

Targeted Drug May Lower Odds for Breast Cancer's Return in Some Patients

Here's some good news for women with the most common type of breast cancer: Adding a targeted breast cancer drug to hormonal therapy reduced the risk of cancer returning by 25% for women with early-stage disease, a new clinical trial shows.

Hormone-receptor (HR) positive/HER2 negative breast cancer accounts for about 70% of breast can...

Opdivo Could Boost Outcomes for People Battling Hodgkin Lymphoma

The widely used immunotherapy drug nivolumab (Opdivo) is safer and more effective in treating adults and children with advanced Hodgkin lymphoma than the targeted therapy now used as standard care is, new clinical trial results show.

Nivolumab outperformed the drug brentuximab vedotin (Adcetris), extending progression-free survival by 94% ...